Skip to content

R&D Leadership

Susan Learned M.D., Pharm.D., Ph.D.

Head, Research and Development

Susan is an extremely accomplished research scientist, medicines developer and pharmaceutical executive with 25 years of pharmaceutical industry experience spanning all phases of drug discovery and development. Susan most recently was the SVP of Global Medicines Development at Indivior. Prior to this, she spent nearly 20 years with GlaxoSmithKline, including the role as VP, Medicines Development Lead and Franchise Head.

Susan is an extremely accomplished research scientist, medicines developer and pharmaceutical executive with 25 years of pharmaceutical industry experience spanning all phases of drug discovery and development.  Susan most recently was the SVP of Global Medicines Development at Indivior, accountable for all discovery, development and life-cycle management strategy and operations across Indivior’s portfolio, as well as key supportive functions.  

Prior to this, she spent nearly 20 years with GlaxoSmithKline, including roles as VP, Medicines Development Lead and Franchise Head, Stiefel, VP and Head, Discovery Medicine Unit in Shanghai, China, Head of Neuroscience Discovery Scientific Licensing for Worldwide Business Development, and Head of Neuroscience Discovery Medicine, North America.  

Susan has led or been an integral part of more than 60 successful NDAs, sNDAs, and global regulatory submissions.

Frank Kondrad

Head, Project Management

A science-based business leader with a broad healthcare background. Former AstraZeneca Executive Director of Business Development and Licensing, Senior Director Clinical Development, Director of Managed Markets, Director of External Medical Relations, NEXIUM Managed Markets and HCP Brand Marketing Leader, CRESTOR Senior Market Research Manager, Global Strategic Planning Manager and Head of CMC Project Management and Regulatory Documentation.

John Wahlich, Ph.D.

Head, CMC/Pharm Dev/MFG

John Wahlich is a CMC professional specializing in oral formulations and the analysis of small molecules. He was formerly VP of Product Line Extensions and VP of Early Pharmaceutical Development in GSK where he worked for 25 years. He has been consulting for numerous companies over the past 10 years. He has a PhD in Pharmaceutics from the University of Nottingham (UK).

Fiona Randall, Ph.D.

Head, Pre-Clinical Neuroscience

Dr. Randall is a renowned neuroscientist, strategic alliance and business development expert with worldwide drug discovery and development experience in the pharmaceutical and biotechnology industry with Merck, GSK, Eisai and Vertex in the USA, UK, China and Japan. Dr. Randall has led multiple preclinical projects in neurology and is currently SVP of External Alliances and Scientific Strategy at Mindset Pharma Inc.

O'Neil D'Cruz
M.D., M.B.A., FAAN

Head, Neurology Clinical Development

Dr. D’Cruz is an experienced epileptologist and clinical investigator who consults with pharmaceutical companies and is on the External Advisory Board for NIH’s NeuroNext Program. Dr. D'Cruz is acting as an independent consultant for Shackelford Pharma. He was previously Professor of Neurology and Pediatrics at University of North Carolina-Chapel Hill, USA. Dr. D'Cruz's previous industry appointments include Medical Director, Neurology at UCB Pharma and Chief Medical Officer, Cyberonics. Member of Pediatric Epilepsy Academic Consortium for Extrapolation, Former BOD of American Society of Experimental Neuro-Therapeutics.

Rebecca Boone, B.S., M.A.

Head, Clinical Operations

Rebecca brings more than 30 years of clinical drug development experience to Shackelford. Previous roles include SVP of Clinical Operations at Asklepios Biopharmaceuticals and VP Global Development Operations at Theravance BioPharma.

Rebecca has worked across Phases I – IV and multiple therapy areas with expertise in strategic planning, global clinical operations, data management, financial planning and management, business process improvement, post-merger and acquisition integration, CRO and vendor management, personnel management, coaching, and leadership.

Susan Sisk, Ph.D., R.A.C.

Regulatory & Technical Writing Consultant

Susan brings over 25 years of experience in designing, writing, and reviewing clinical trial protocols, Investigational New Drug applications and annual reports, investigator’s brochures, clinical study reports (Phase 1-4), integrated summaries and other New Drug Application components, and packages for sponsor meetings with Food and Drug Administration personnel.

Judith Jaeger, Ph.D., M.P.A.

Clinical Development & Psychometrics Consultant

Judith Jaeger is a neuropsychologist with more than 35 years’ experience in clinical and experimental neuropsychology and psychopathology. She is owner and president of CognitionMetrics, LLC, a consultancy serving the pharmaceutical industry with expertise on cognitive and behavioural measurement in the context of drug development. She is Clinical Professor of Psychiatry and Behavioral Science at Albert Einstein College of Medicine, New York and the author of over 80 peer reviewed journal articles, several book chapters, co-edited books and hundreds of abstracts and presentations.

Judith Jaeger is a neuropsychologist with more than 35 years’ experience in clinical and experimental neuropsychology and psychopathology. She is owner and president of CognitionMetrics, LLC, a consultancy serving the pharmaceutical industry with expertise on cognitive and behavioural measurement in the context of drug development. She is Clinical Professor of Psychiatry and Behavioral Science at Albert Einstein College of Medicine, New York and the author of over 80 peer reviewed journal articles, several book chapters, co-edited books and hundreds of abstracts and presentations. 

Previously she was Vice President for Clinical Trials at Cogstate, Inc. and Director of Clinical Development at AstraZeneca Pharmaceuticals where she served as company-wide cognition and psychometrics expert. These industry positions followed a distinguished academic career as an NIH funded research clinician and educator. 

Since forming CognitionMetrics, she has advised numerous pharmaceutical companies on early phase and experimental medicine projects as well as pivotal and late phase clinical programs in Alzheimer and other dementias, neurodegenerative and neurodevelopmental diseases, ADHD, schizophrenia, bipolar disorder, major depression and oncology. 

She has represented pharmaceutical clients in regulatory meetings including the FDA and Japan’s PMDA and has been a key presenter at an FDA Advisory Committee meeting.

 

Michael Shannon
M.A., M.Sc., M.D.

Scientific Advisory Board

Dr. Shannon received his medical degree from Queen’s University in Canada, which included advanced training in surgery and sports medicine. He also holds post-graduate degrees in neurochemistry and physiology. He has been actively engaged in applied medical research within these areas for 30 years.

Dr. Shannon received his medical degree from Queen’s University in Canada, which included advanced training in surgery and sports medicine. He also holds post-graduate degrees in neurochemistry and physiology. He has been actively engaged in applied medical research within these areas for 30 years.

Dr. Shannon also spent 31 years in the Canadian Forces and retiring at the rank of Commodore (Brigadier General equivalent) and also had the responsibility of being Deputy Surgeon General for Canada. He assumed responsibilities within Health Canada for re-organizing the Canadian blood system. Working with both the provincial and federal governments he oversaw the development of a new corporate entity dedicated exclusively to the management of blood services in Canada. He was then appointed Director General for the Laboratory Centre for Disease Control, a position he held for three years.

Dr. Shannon left the Canadian federal government in 2001 to pursue a new career in industry and gained significant experience successfully managing numerous multinational, multi centered phase III clinical trials in Canada, the United States and Great Britain. 

Following completion of that work, he served as an Audit Principal and Senior Medical Advisor to the Canadian Auditor General and then accepted responsibilities for rebuilding the Emergency Medical Response System withing the newly formed Public Health Agency of Canada. 

Dr. Shannon has been actively engaged in medical bio-oxidative (O3 based) research since 1987 and was directly responsible for the first human clinical trial to have ever been approved in North America which examined the efficacy of O3 delivered via minor autohemotherapy in the treatment of AIDS. He was also responsible for several primate studies utilizing O3 involving scientists from various departments within the Canadian Federal Government and Cornell University.

Dr Shannon has worked in the area of hospital disinfection for eight years, is coinventor of a new trioxidane-based broad spectrum decontamination system that has recently secured full US EPA approval, and is now engaged in completing a de novo FDA 510K submission.

 

Invest in Shackelford

Shackelford Pharma’s Regulation A Financing is now open. Investors are required to fill out the form below to begin the investment process.

Please check your JUNK/SPAM email folder if your invitation email from Dealmaker/Shackelford does not arrive in your inbox.

Invest Shackelford